DEVELOPMENT AND VALIDATION OF STABILITY INDICATING CHROMATOGRAPHIC METHOD FOR SIMULTANEOUS ESTIMATION OF SACUBITRIL AND VALSARTAN IN PHARMACEUTICAL DOSAGE FORM
DOI:
https://doi.org/10.22159/ijap.2017v9i5.19139Keywords:
Sacubitril, Valsartan, RP-HPLC, Stability indicating RP-HPLC method, ValidationAbstract
Objective: This study aims to develop and validate a stability indicating HPLC method for simultaneous estimation of sacubitril and valsartan in pharmaceutical dosage form.
Methods: Sacubitril and valsartan separation were achieved by LC-20 AT C18 (250 mm x 4.6 mm) column and buffer (potassium phosphate, pH 3.0): methanol (50:50) as mobile phase, at a flow rate of 1 ml/min (millilitre per minute). Detection was carried out at 224 nm (nanometer). The different HPLC experimental parameters were optimized and the method was validated according to the standard guideline. Forced degradation experiments were carried out by exposing sacubitril and valsartan standard and sample for thermal, photolytic, oxidative and acid-base hydrolytic stress conditions.
Results: Retention time of sacubitril and valsartan were found to be 4.170 min (minute) and 6.530 min (minute) respectively. The method has been validated for linearity, accuracy, precision, LOD, and LOQ. Linearity observed for sacubitril is 12.25-36.75 μg/ml (microgram per milliliter) and for valsartan is 12.75-38.25 μg/ml (microgram per milliliter). The results showed that sacubitril and valsartan and the other degradation products were fully resolved and thus the proposed method is stability-indicating.
Conclusion: The proposed HPLC method was found to be simple, specific, precise, accurate, rapid and economical for simultaneous estimation of valsartan and sacubitril in bulk and tablet dosage form. Thus the validated economical method was applied for forced degradation study of sacubitril and valsartan tablet.
Downloads
References
National Center for Biotechnology Information. PubChem Compound Database; CID=9811834. Available from: https:// pubchem.ncbi.nlm.nih.gov/compound/9811834. [Last accessed on 10 Mar 2017].
Voors AA, Dorhout B, Van Der Meer P. The potential role of valsartan+AHU377 (LCZ696) in the treatment of heart failure. Expert Opin Invest Drugs 2013;22:1041-7.
Novartis AG. Novartis’ new heart failure medicine LCZ696, now called Entresto, approved by FDA to reduce the risk of cardiovascular death and heat failure hospitalisation. Available fromhttps://www.novartis.com/news/media-releases/Novartis- new-heart-failure-medicine-lcz696-now-called-entrestotm-approved-fda. [Last accessed on 10 Mar 2017].
Budavari S. The Merck index. 14th ed. Whitehouse Station. NJ Merck and Co. Press; 2006.
Neil MJ, Smith A, Heckelman PE, Kinneary JF. The Merck Index: An Encyclopedia of Chemicals. Edition. 14. Drugs and Biologicals; 2006. p. 1767.
Criscione L, Bradley W, Buhlmayer P, Whitebread S, Glazer R, Lloyd P, et al. Clinical advantage of valsartan. Drug Rev 1995;13:230-50.
The United States Pharmacopoeia. 31, National Formulary, 26. Vol. 2. US Pharmacopoeia Convention, INC: Rockville M; 2008. p. 3496-8.
Kocyigit Kaymacoglu B, Unsalan S, Rollas S. Determination and validation of ketoprofen, pantoprazole, and valsartan together in human plasma by high-performance liquid chromatography. Pharmazie 2006;61:586-9.
Daneshtalab N, Lewanczuk RZ, Jamali F. High performance liquid chromatographic analysis of angiotensin-II receptor antagonist valsartan using a liquid extraction method. J Chromatogr B: Anal Technol Biomed Life Sci 2002;766:345-59.
Gonzalez L, Lopez JA, Alonso RM, Jimenez RM. Fast screening method for the determination of angiotensin II receptor antagonists in human plasma by high-performance liquid chromatography with fluorimetric detection. J Chromatogr A 2002;8:49-60.
Koseki N, Kawashita H, Hara H, Niina M, Tanaka M, Kawai R, et al. Development and validation of a method for quantitative determination of valsartan in human plasma by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2007;43:1769-74.
Li H, Wang Y, Jiang Y, Tang Y, Wang J, Zhao L, et al. A liquid chromatography/tandem mass spectrometry method for the simultaneous quantification of valsartan and hydro-chlorothiazide in human plasma. J Chromatogr B: Anal Technol Biomed Life Sci 2007;852:436-42.
Macek J, Klima J, Ptacek P. Rapid determination of valsartan in human plasma by protein precipitation and high-performance liquid chromatography. J Chromatogr B: Anal Technol Biomed Life Sci 2006;832:169-72.
Satana E, Altinay S, Goger NG, Ozkan SA, Sentürk Z. Simultaneous determination of valsartan and hydrochlorothiazide in tablets by first-derivative ultraviolet spectrophotometry and LC. J Pharm Biomed Anal 2001;5:1009-13.
Tatar S, Saglik S. Comparison of UV-and second derivative-spectrophotometric and LC methods for the determination of Valsartan in a pharmaceutical formulation. J Pharm Biomed Anal 2002;30:371-5.
Chunduri RHB, Dannana GS. Development and validation of a reliable and rapid LC-MS/MS method for simultaneous quantification of sacubitril and valsartan in rat plasma and its application to a pharmacokinetic study. Biomed Chromatogr 2016;30:1467–75.
Kena H Patel, Shailesh V, Luhar, Sachin B Narkhede. Simultaneous estimation of sacubitril and valsartan in the synthetic mixture by the RP-HPLC method. J Pharm Sci Biosci Res 2016;6:262-9.
ICH guidelines for the stability of new drug substances and products. Q1A(R2) ICH, Geneva; 2005. p. 1-13.
ICH guidelines for validation of analytical procedures: text and methodology. Q2(R1) ICH, Geneva; 2005. p. 1-14.
Bhatia MS, Kokil SU. Determination and validation of valsartan and its degradation products by isocratic HPLC. J Chem Met 2009;3:1-12.
Published
How to Cite
Issue
Section
